ClearStar,Inc. Launch of COVID-19 testing service for employers (5524N)
21 Mayo 2020 - 1:00AM
UK Regulatory
TIDMCLSU TIDMTTM
RNS Number : 5524N
ClearStar,Inc.
21 May 2020
21 May 2020
ClearStar, Inc.
("ClearStar" or the "Company")
ClearStar launches COVID-19 testing service for employers
New COVID-19 testing programme to assist employers with
return-to-work process and workforce safety
ClearStar (AIM: CLSU), a provider of Human Capital IntegritySM
technology-based services specialising in background and medical
screening , announces the launch of a testing service aimed at
supporting employers with their COVID-19 return-to-work planning
and keeping their workforce safe. The new service is provided by
ClearStar's Medical Information Services ("MIS") business through
Clinical Reference Laboratory, Inc. ("CRL"), one of the largest
privately held clinical testing laboratories in the US, and it
includes both an antibody and a diagnostic test.
In the first instance, employees receive the CRL Clear(TM) kit,
which is a dried blood spot finger prick test that is used to
identify the presence, or lack, of COVID-19 antibodies in the
blood, which are produced by the body in response to the virus.
This includes IgA, IgM and IgG antibodies, which are produced at
different stages of the immune system response. A positive test
result indicates that the employee has been previously infected by
COVID-19 and has developed antibodies that might provide the
employee with immunity. The CRL Clear(TM) kit is based on the Roche
Elecsys(R) Anti-SARS-CoV-2 antibody test, which has received the CE
mark and US Food and Drug Administration Emergency Use
Authorization.
Employees testing positive for the CRL Clear(TM) test, or those
initially displaying symptoms, receive the CRL Rapid Response(TM)
kit, which is a saliva-based molecular diagnostic test to determine
if the virus is active. Those testing positive, meaning they are
currently infected with COVID-19, will automatically be contacted
by a licenced doctor to discuss the results and next steps. Any
employee testing positive at either stage also receives
instructions on self-isolation.
The Company's customers are able to order the tests using the
same process as for their existing ClearStar drug and clinical
screening programmes. Test collection kits are shipped either in
bulk to the employer or direct to the employees (or job
applicants), with the samples being self-collected by the employee
and sent back to the CRL lab for testing. Employees also complete a
questionnaire ahead of receiving the test collection kit and
subsequently register the test collection kit online. The results
of the tests are reported via the ClearStar platform within 24
hours, on average, of the samples being received by the lab and are
provided in the same format, based on employer preference, as the
customer receives their other drug or background screening reports
from the Company.
Robert Vale, CEO of ClearStar, said: "Balancing the equally
important goals of getting people back to work and ensuring their
safety and well-being is top priority for employers. We are proud
to be able to offer our customers a new COVID-19 testing service,
and by partnering with Clinical Reference Laboratory, whose tests
are easy to self-administer, we can offer a reliable and quick
turnaround. This new service - alongside our existing suite of
background and medical screening solutions - will help employers to
make more informed hiring and return-to-work decisions to get
people into work quicker while maintaining public safety."
Enquiries:
ClearStar, Inc. +1 877 796 2559
Robert Vale, Chief Executive Officer
Jennifer Balleza, Chief Financial Officer
-----------------
finnCap Ltd. +44 20 7220 0500
-----------------
Jonny Franklin-Adams, Marc Milmo, Simon Hicks
- Corporate Finance
Andrew Burdis, Tim Harper - ECM
-----------------
Luther Pendragon +44 20 7618 9100
-----------------
Harry Chathli, Claire Norbury, Joe Quinlan
-----------------
About ClearStar
ClearStar, Inc. is a leading provider of Human Capital
IntegritySM technology-based services specialising in background
and medical screening. It provides employment intelligence direct
to employers and via channel partners/consumer reporting agencies
("CRAs") to support better recruitment and other decisions
affecting employees by increasing the quality, reliability and
visibility of information.
A seven-time Inc. 5000 honouree and founding member of the
Professional Background Screening Association, ClearStar has
provided innovative technology solutions to businesses in the human
capital management industry from its corporate offices in
Alpharetta, Georgia since 1995. For more information about
ClearStar, please visit: www.clearstar.net .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDKKKBQDBKBQPB
(END) Dow Jones Newswires
May 21, 2020 02:00 ET (06:00 GMT)
Clearstar (LSE:CLSU)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Clearstar (LSE:CLSU)
Gráfica de Acción Histórica
De May 2023 a May 2024